Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: Evidence from in Vitro breast cancer cell models

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2036-2045

  Fan, Ping ^a   Yue, Wei ^a   Wang, Ji Ping ^a   Aiyar, Sarah ^a   Li, Yan ^a   Kim, Tae Hyun ^a   Santen, Richard J ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM EXPOSURE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; BREAST TUMOR; CHEMISTRY; CULTURE TECHNIQUE; DRUG RESISTANCE; FEMALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; TAMOXIFEN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 66449117772     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1195     Document Type: Article

References (44)

1. Fan P, Wang J, Santen RJ, Yue W 2007 Long-term treatment with tamoxifen facilitates translocation of estrogen receptor a out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:1352-1360
2. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD 2004 Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 92:63-71
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044
4. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142:2776-2788
5. Pink JJ, Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
6. Katzenellenbogen BS 1991 Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83:1434-1435
7. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, LippmanJ, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R 1997 MCF7/LCC9: an antiestro- gen-resistant MCF-7 variant in which acquired resistance to the steroidal an- tiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 57:3486-3493
8. Lykkesfeldt AE, Madsen MW, Briand P 1994 Altered expression of estrogen- regulated genes in a tamoxifen-resistant and ICI 164, 384 and ICI 182, 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:1587-1595
9. Osborne CK, Coronado E, AllredDC, Wiebe V, DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamox- ifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482
10. Jeng MH, Shupnik MA, BenderTP, Westin EH, Bandyopadhyay D, KumarR, Masamura S, Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139: 4164-4174
11. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ 2001 Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17/3-estradiol. J Natl Cancer Inst 93:1714-1723
12. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ2002 Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143:3221-3229
13. Sawka CA, Pritchard KI, Paterson AH, Sutherland DJ, Thomson DB, Shelley WE, MyersRE, MobbsBG, MalkinA, MeakinJW1986 Roleandmechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46:3152-3156
14. Lee JS, Ettinger B, Stanczyk FZ, Vittinghoff E, Hanes V, Cauley JA, Chandler W, Settlage J, Beattie MS, Folkerd E, Dowsett M, Grady D, Cunnings SR 2006 Comparison of methods to measure low serum estradiol levels in postmeno- pausal women. JClin Endocrinol Metab 91:3791-3797
15. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S 2007 Superiority of gas chromatography/tandem mass spectrom- etry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72:666 -671
16. Stanczyk FZ, Lee JS, Santen RJ 2007 Standardization of steroid hormone assays: why, how and when? Cancer Epidemiol Biomarkers Prev 16:1713-1719
17. Spink DC, Katz BH, Hussain MM, Pentecost BT, Cao Z, Spink BC 2003 Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells. Carcinogenesis 24:1941-1950
18. Santner SJ, Ohlsson-Wilhelm B, Santen RJ 1993 Estrone sulfate promotes human breastcancer cellreplicationand nuclear uptakeofestradiolinMCF-7 cell cultures. Int JCancer 54:119-124
19. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2496-2500
20. Welshons WV, Wolf MF, Murphy CS, Jordan VC 1988 Estrogenic activityof phenol red. Mol Cell Endocrinol 57:169-178
21. Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G 1976 Free and protein-bound plasma estradiol-17/3 during the menstrual cycle. J Clin Endocrinol Metab 43:436-445
22. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP 2006 Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966
23. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS 2006 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66:7334-7340
24. Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC2006Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379-386
25. Borgna JL, Rochefort H 1980 High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell En- docrinol 20:71-85
26. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP 1999 Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828 -5840
27. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266 -1274
28. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Veld A, van't Veer L, Neefjes J 2004 Tamoxifen resistance by a conformational arrest of the estrogen receptor a after PKA activation in breast cancer. Cancer Cell 5:597-605
29. Dauvois S, Danielian PS, White R, Parker MG 1992 AntiestrogenICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
30. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI 2006 Bidirectional cross talk between ERa and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131-146
31. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, SchiffR 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
32. Yue W, Berstein LM, Wang JP, Clark GM, Hamilton CJ, Demers LM, Santen RJ 2001 The potential role of estrogen in aromatase regulation in breast. J Steroid Biochem Mol Biol 79:157-164
33. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG 1990 Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883-6887
34. Dauvois S, White R, Parker MG 1993 The antiestrogen ICI 182, 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
35. Brooks SC, Locke ER, Soule HD 1973 Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251-6253
36. Soule HD, Vazguez J, Long A, Albert S, Brennan M 1973 A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409-1416
37. Larsen SS, Egeblad M, Jaattela M, Lykkesfeldt AE 1999 Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58:41-56
38. Osipo C, Gajdos C, Cheng D, Jordan VC2005 Reversal oftamoxifenresistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 93: 249-256
39. Hsu SC, Hung MC 2007 Characterization of a novel tripartite nuclear localization sequence in the EGFR family. JBiol Chem 282:10432-10440
40. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC 2006 Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, im- portin 01 and CRM1. J Cell Biochem 98:1570-1583
41. Larionov AA, Berstein LM, Miller WR 2002 Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. J Steroid Biochem Mol Biol 81:57-64
42. Yue W, Wang JP, HamiltonCJ, Demers LM, SantenRJ 1998 In situ aroma- tization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58:927-932
43. Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ 1997Aromataseactivityand expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 82:200-208
44. van Landeghem AA, Poortman, J, Nabuurs M, Thijssen JH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:2900 -2906